Thus, we can readily envision a future in which T1D and T2D therapy may include combinations of DYRK1A inhibitors with calcium channel blockers, TIXNIP inhibitors, dextran sulfate, senolytics, immunomodulatory antibodies and/or immunosuppressant small molecules. Here, DYRK1A is linked to type 2 diabetes mellitus.